Ref: GLL/BSE/2020/Sep-07

To
Corporate Relations Manager
BSE Limited
Phiroje Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001

To
The Secretary
The Calcutta Stock Exchange Limited
#7, Lyons Range, Murgighata,
Dalhousie, Kolkata – 700 001

Sub: Outcome of the Board Meeting held on September 15, 2020 of Gennex Laboratories Limited
Ref: Regulation 33 & 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/Ma’am,

In just concluded Meeting of the Board Directors of the Company, the board has considered and approved:

1. Unaudited (Standalone and Consolidated) Financial Statements for the Quarter ended June 30, 2020 (annexed herewith);
2. Limited review reports from the Statutory Auditor on Unaudited (Standalone and Consolidated) Financial Statements for the Quarter ended June 30, 2020 (annexed herewith).

This intimation is also uploaded in the Company website: www.gennexlab.com.

We request you to take the above information on record and acknowledge the receipt of the same.

Thanking you,
Yours Truly,

For Gennex Laboratories Limited

Rajesh Vankadara
Company Secretary &
Compliance Officer
Membership #A44949
| S No. | PARTICULARS | Standalone | | | Consolidated | | | | | Quarter ended | Year ended | Quarter ended | Year ended | Quarter ended | Year ended |
|-------|-------------|------------|----|----|------------|----|----|----|----|------------|------------|----|----|------------|------------|----|----|------------|------------|
| 1     | Income     |            |    |    |            |    |    |    |    |            |            |    |    |            |            |    |    |            |            |
|       | Revenue from Operations | 1304.63 | 1145.32 | 1608.73 | 5561.73 | 1304.63 | 1145.32 | 1608.73 | 5561.73 |            |            |    |    |            |            |    |    |            |            |
|       | Other Income | 14.77 | 18.06 | 34.18 | 95.14 | 14.77 | 18.06 | 34.18 | 95.14 |            |            |    |    |            |            |    |    |            |            |
| 2     | Total Income | 1319.40 | 1163.38 | 1642.91 | 5656.87 | 1319.40 | 1163.38 | 1642.91 | 5656.87 |            |            |    |    |            |            |    |    |            |            |
| 3     | Expenses   |            |    |    |            |    |    |    |    |            |            |    |    |            |            |    |    |            |            |
|       | (a) Cost of material consumed | 652.51 | 738.64 | 1030.07 | 3513.11 | 652.51 | 738.64 | 1030.07 | 3513.11 |            |            |    |    |            |            |    |    |            |            |
|       | (b) Purchase of stock-in-trade | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |            |            |    |    |            |            |    |    |            |            |
|       | (c) Changes in stock-in-trade and Work in Progress and stock in trade | 196.74 | 18.63 | -97.55 | -151.11 | 196.74 | 18.63 | -97.55 | -151.11 |            |            |    |    |            |            |    |    |            |            |
|       | (d) Employees Cost | 155.10 | 154.66 | 170.13 | 681.19 | 155.10 | 154.66 | 170.13 | 681.19 |            |            |    |    |            |            |    |    |            |            |
|       | (e) Depreciation | 21.98 | 19.03 | 25.42 | 100.50 | 21.98 | 19.03 | 25.42 | 100.50 |            |            |    |    |            |            |    |    |            |            |
|       | (f) Finance Cost | 16.02 | 15.38 | 22.92 | 75.36 | 16.02 | 15.38 | 22.92 | 75.36 |            |            |    |    |            |            |    |    |            |            |
|       | (g) Other Expenses | 226.01 | 177.59 | 385.18 | 1193.82 | 226.01 | 177.59 | 385.18 | 1193.82 |            |            |    |    |            |            |    |    |            |            |
| 4     | Total Expenses | 1268.36 | 1123.93 | 1536.17 | 5412.87 | 1268.36 | 1123.93 | 1536.17 | 5412.87 |            |            |    |    |            |            |    |    |            |            |
| 5     | Profit before exceptional items & Tax. | 51.04 | 39.45 | 106.74 | 244.00 | 51.04 | 39.45 | 106.74 | 244.00 |            |            |    |    |            |            |    |    |            |            |
| 6     | Exceptional items | 0.00 | 0.00 | 0.00 | 10.86 | 0.00 | 0.00 | 0.00 | 10.86 |            |            |    |    |            |            |    |    |            |            |
| 7     | Total profit before tax | 51.04 | 39.45 | 106.74 | 254.86 | 51.04 | 39.45 | 106.74 | 254.86 |            |            |    |    |            |            |    |    |            |            |
| 8     | Tax expense for earlier years | 0.00 | -10.34 | 0.00 | -10.34 | 0.00 | -10.34 | 0.00 | -10.34 |            |            |    |    |            |            |    |    |            |            |
| 9     | Current tax | -14.20 | -15.00 | -27.00 | -75.00 | -14.20 | -15.00 | -27.00 | -75.00 |            |            |    |    |            |            |    |    |            |            |
| 10    | Deferred Tax | 0.00 | 16.12 | 0.00 | 16.12 | 0.00 | 16.12 | 0.00 | 16.12 |            |            |    |    |            |            |    |    |            |            |
| 11    | Total Tax Expenses | -14.20 | -15.00 | -27.00 | -91.22 | -14.20 | -15.00 | -27.00 | -91.22 |            |            |    |    |            |            |    |    |            |            |
| 12    | Net profit (Loss) | 36.84 | 30.23 | 79.74 | 185.64 | 36.84 | 30.23 | 79.74 | 185.64 |            |            |    |    |            |            |    |    |            |            |
| 13    | Share of profit (loss) of associates and joint ventures accounted for using equity method | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |            |            |    |    |            |            |    |    |            |            |
| 14    | Total Profit (loss) for period | 36.84 | 30.23 | 79.74 | 185.64 | 36.84 | 30.23 | 79.74 | 185.64 |            |            |    |    |            |            |    |    |            |            |
| 15    | Other comprehensive income net of taxes |            |            |            |            |            |            |            |            |            |            |    |    |            |            |    |    |            |            |
| 16    | Total Comprehensive income for the period |            |            |            |            |            |            |            |            |            |            |    |    |            |            |    |    |            |            |
| 17    | Details of equity share capital |            |            |            |            |            |            |            |            |            |            |    |    |            |            |    |    |            |            |
|       | Paid up equity share capital | 1265.03 | 1265.03 | 1265.03 | 1265.03 | 1265.03 | 1265.03 | 1265.03 | 1265.03 |            |            |    |    |            |            |    |    |            |            |
|       | Face value of equity share capital | 0.0001 | 0.0001 | 0.0001 | 0.0001 | 0.0001 | 0.0001 | 0.0001 | 0.0001 |            |            |    |    |            |            |    |    |            |            |
| 18    | Earnings per share |            |            |            |            |            |            |            |            |            |            |    |    |            |            |    |    |            |            |
|       | - Basic | 0.029 | 0.024 | 0.063 | 0.147 | 0.029 | 0.024 | 0.063 | 0.147 |            |            |    |    |            |            |    |    |            |            |
|       | - Diluted | 0.029 | 0.024 | 0.063 | 0.147 | 0.029 | 0.024 | 0.063 | 0.147 |            |            |    |    |            |            |    |    |            |            |
1. The above unaudited financial results have been reviewed by the Audit Committee of its meeting held on 15.09.2020 and the same were approved and taken on record by the Board of Directors at its meeting held on the same day.

2. The Statutory Auditors of the Company have carried out the Limited review of the above unaudited financial results for the Quarter ended June 30, 2020.

3. The above results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (IND-AS) prescribed u/s 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.

4. Operations and financial results of the Company for the quarter ended June 30, 2020 have been adversely impacted due to frequent lockdown imposed by the Central and/or State Governments in various parts of the country to control the spread of Covid-19. Since the operations have gradually but partially resumed during the quarter with limited availability of workforce and the resources, the results for the quarter are not comparable with those for the previous quarters.

The Company has taken into account the possible impacts of Covid-19 in preparation of the financial results for the quarter ended June 30, 2020, including but not limited to its assessment of liquidity, recoverable values of its financial and non-financial assets and impact of revenues.

At present, the Company is operating at optimum level of production capacity.

5. The figure for the quarter ended March 31, 2020 are the balancing figure between the audited figures in respect of the full financial year and published year to date figure up to December 31, 2019. Also, figures up to end of the quarter December 31, 2019 were only reviewed and not subject to audit.

6. The management has assessed the identification of reportable segments in accordance with the requirement of the Ind AS 108 Operating Segment and believes that the Company has only one reportable segment namely "Bulk Drugs, Biotech Products and Intermediates". Previous period's figures have been rearranged / regrouped wherever necessary.

7. Adjustment of actuarial valuation in respect of compliance with revised Accounting Standard - IAS - 19 - 'Employee Benefits' is to be done at the year end.

8. The value of Stock is as certified by the management.

9. The quarterly unaudited Financial results for the quarter ended June 30, 2020 are available on the Company's Website i.e., www.gennexlab.com and also available on BSE website i.e., www.bseindia.com.

Date: 15.09.2020
Place: Hyderabad

For and on Behalf of the Board
Gennex Laboratories Limited

M. Gopalakrishnan
Whole-time Director
DIN: 00044212
Independent Auditor’s Review Report On consolidated unaudited quarterly and year to date financial results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To The Board of Directors,
Gennex Laboratories Limited,
Hyderabad.

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of Gennex Laboratories Limited ("the Company") and its share of the net profit after tax and total comprehensive income of its associate for the quarter ended 30th June 2020 being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. Attention is drawn to the fact that the consolidated figures for the corresponding quarter ended 30th June 2020 as reported in these financial results have been approved by the Company’s Board of Directors, but have not been subjected to review.

2. This Statement, which is the responsibility of the Company’s Management and approved by the Company’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “Interim Financial Reporting” ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “Review of Interim Financial Information Performed by the Independent Auditor of the Entity”, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of Deccan Remedies Limited. (Associate Company)
5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standard specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. The accompanying unaudited consolidated financial results includes unaudited interim financial results and other unaudited financial information in respect of 1 Associate, which have been reviewed by their auditors, whose interim financial results excluding consolidation eliminations reflect total revenues of Rs. 0.00 lakhs, total net Profit after tax of Rs. 0.00 lakhs and total comprehensive Profit of Rs. 0.00 lakhs, for the quarter ended June 30, 2020 as considered in the unaudited consolidated financial results. These unaudited financial results and other unaudited financial information have been approved and furnished to us by the management. Our conclusion, in so far as it relates to the affairs of these Associates, is based solely on such unaudited financial results and other unaudited financial information. According to the information and explanations given to us by the Management, these interim financial results are not material to the Group. Our conclusion on the Statement is not modified in respect of the above matter.

For PPKG & Co
Chartered Accountants
FRN No. 009655S

Girdhari Lal Toshniwal
(Partner)
M.No. 205140
UDIN: 20205140AAAAFK3951

Place: Hyderabad
Date: 15/09/2020
Limited Review report

To
The Board of Directors,
Gennex Laboratories Limited,
Hyderabad.

We have reviewed the accompanying statement of unaudited financial results of Gennex Laboratories Limited for the Quarter ended 30th June 2020. This statement is the responsibility of the Company’s Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “Review of Interim Financial Information Performed by the Independent Auditor of the Entity”, issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data, thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For PPKG & Co.
Chartered Accountants
FRN No. 009655S

Girdhari Lal Toshniwal
(Partner)
M.No. 205140
UDIN: 20205140AAAAF7311

Place: Hyderabad
Date: 15/09/2020